Broad-spectrum influenza vaccine antigen fragments, recombinant probiotics and their applications

By expressing and secreting the influenza virus M2e antigen fragment through the probiotic Nissle 1917, the recombinant strain EcN-5M2e was constructed, which solved the problems of delayed influenza vaccine production and safety, and achieved efficient preparation and cross-protection of broad-spectrum influenza vaccines, which is suitable for large-scale rapid production and mucosal immunization.

CN118530314BActive Publication Date: 2025-09-30WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
1 Cites 0 Cited by

Patent Information

Application Number
CN202410732313.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-06
Publication Date
2025-09-30
Estimated Expiration
2044-06-06

AI Technical Summary

Technical Problem

Existing influenza vaccines are unable to respond quickly to seasonal epidemics or outbreaks of influenza viruses, and cross-species influenza viruses such as avian influenza and swine influenza viruses require the development of broad-spectrum vaccines. Traditional vaccine production technology has lags, and the use of animal-derived viruses poses safety risks.

Method used

The probiotic Nissle 1917 (EcN) was used as a vector to express and secrete the influenza virus M2e antigen fragment. Immunization was performed via nasal drops, and the HlyABD secretion system and optimized signal peptide were used to deliver the 5M2e antigen fragment to the extracellular space. The recombinant probiotic strain EcN-5M2e was constructed to achieve the preparation of a broad-spectrum influenza vaccine.

Benefits of technology

It achieves efficient protection against multiple influenza viruses, simplifies the vaccine production process, improves biosafety and immune effects, is suitable for large-scale and rapid production, and induces strong immune responses through mucosal immune pathways, providing cross-protection efficacy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention discloses a broad-spectrum influenza vaccine antigen fragment, recombinant probiotics and applications. The present invention utilizes the high conservation of the M2e sequence in different subtypes of influenza viruses and is expected to develop into a broad-spectrum influenza vaccine with cross-protection efficacy. The probiotic Escherichia coli EcN is used to express and secrete the 5M2e antigen. The vaccine preparation process does not involve live viruses. Compared with the traditional chicken embryo influenza vaccine preparation method, the operation is safer and simpler, and it is suitable for rapid large-scale production. The vaccine of the present invention can be immunized by nasal drops. Compared with the commonly used intramuscular injection immunization route, it is safer and simpler to use, and is closer to the natural invasion route of influenza viruses into the host, which is conducive to inducing mucosal immune responses.
Need to check novelty before this filing date? Find Prior Art